1. Scrip

Gritstone, Gilead Partner To Develop Therapeutic HIV Vaccine

Deal Closely Follows COVID-19 Vaccine Effort

 
• By Alaric DeArment

Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.

HIV Vaccine
Gritstone and Gilead are partnering to develop a therapeutic HIV vaccine. • Source: Shutterstock

Less than two weeks after announcing it would seek to develop a vaccine to prevent new resistant strains of SARS-CoV-2, Gritstone Oncology, Inc. is applying the same platform technology as it embarks on another challenging path – developing a therapeutic vaccine with the goal of curing HIV – under a partnership with Gilead Sciences, Inc. potentially worth nearly $800m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.